Vizsgálati helyszín
IDOR - Regional Sao Paulo
São Paulo, 01401 002, BrazíliaMég nincs intézményhez kötve
Az itteni vizsgálatok
Miről szól a helyszín 10 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis8 vizsgálat
- 1/2. fázis1 vizsgálat
- 2. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz6 vizsgálat
- Toboroz4 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC10 vizsgálat
Futó vizsgálatok
Toboroz
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
NCT06500884· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560· 1/2. fázis· Janssen Research & Development, LLC· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek